GE HealthCare · 1 day ago
Global Regulatory Lead Pharmaceutical Development
Maximize your interview chances
AppsHealth Care
Growth Opportunities
Insider Connection @GE HealthCare
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Lead assigned global program development regulatory strategy and co-ordinate with National Regulatory Affairs (NRA) regulatory submission readiness.
Working with NRA, ensure timely GRA input to global development programs.
For assigned programs/projects, identify regulatory opportunities, potential risks, and mitigations.
Guide, influence and motivate, internal and external stakeholders to meet GE HealthCare business and development project team objectives.
Fulfillment of RA compliance obligations.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
Proven track record of leading successful Pan European (CP, DCP, MRP), European national and US NDA/BLA licensing submissions
Proven track record of leading successful interaction with HA and relevant stakeholders.
Proven expertise with clinical related regulations/guidance as it relates to development of product submissions.
Knowledge of preclinical and CMC as it relates to development of product submissions
Knowledge of regulatory frameworks and external environments as it applies to project specific global regulatory strategy document (GRSD) delivery.
Ability to drive new regulatory approaches to improve and expedite development products submissions to meet business/project objectives and patient needs.
Ability to clearly convey and exchange information with internal and external stakeholders.
Company
GE HealthCare
GE Healthcare provides a wide range of medical technologies and services to healthcare providers and researchers. It is a sub-organization of General Electric.
Funding
Current Stage
Public CompanyTotal Funding
$4.35BKey Investors
Bill & Melinda Gates Foundation
2024-09-12Post Ipo Secondary· $1.29B
2024-02-16Post Ipo Secondary· $1.07B
2023-09-18Grant· $44M
Leadership Team
Recent News
2024-11-14
Company data provided by crunchbase